Skip to main content
Equibles
SLN logo

SLN · Silence Therapeutics plc · Metrics

Track SLN — free

Use SLN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SLN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$19.78 +0.00 (+0.00%) At close · Oct 27 Q4 2024 earnings call transcript
Rebalance outlook locked
Market Cap
$1.23B
Shares
62.20M
Volume · Oct 27 1.49M Avg daily vol (3M) 2.69M

SLN metrics

82 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$19.78
Market cap
$1.23B

Price action

20 metrics
Price change (1W)
+0.9%
Price change (30D)
+76.6%
Price change (3M)
+71.3%
Price change (6M)
+156.9%
Price change (YTD)
+225.3%
Price change (1Y)
+177.0%
Trailing year
Price change (5Y)
-9.3%
52-week high
$19.78
52-week low
$4.30
Change from 52-week high
+0.0%
Change from 52-week low
+360.0%
Annualized volatility
150.4%
Annualized volatility (3M)
260.2%
Beta
1.7
RSI (14D)
79.8
Price vs SMA 50
+50.8%
Price vs SMA 200
+123.6%
Avg volume (3M)
2.69M
Relative volume
0.6
Average dollar volume
$45.02M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
62.20M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1,880.9×
reciprocal yield 0.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
1,998.1×
reciprocal yield 0.1%
P / book
31.9
reciprocal yield 3.1%
FCF yield
-3.4%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-4.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
973.3×
reciprocal yield 0.1%
EV / revenue historical average (5Y)
973.3×
reciprocal yield 0.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-10

Profitability

9 metrics
Gross margin
85.9%
Operating margin
-11,106.8%
Trailing 12 months
Net margin
-9,748.5%
Gross profit (TTM)
$528,000
Operating profit (TTM)
−$68.31M
Net income (TTM)
−$59.95M
Trailing 12 months
Diluted EPS (TTM)
$-1.32
FCF margin
-6,872.5%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.01
Gross profit per diluted share (TTM)
$0.01
Operating profit per diluted share (TTM)
$-1.45
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.27
Operating cash flow per diluted share (TTM)
$-0.89
Free cash flow per diluted share (TTM)
$-0.89
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$1.01
Stock compensation per diluted share (TTM)
—
Book value per share
$1.32

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$615,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.0%
Year over year · more shares
Revenue CAGR (3Y)
-70.4%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-155.8%
Return on assets
-56.3%
Debt / equity
0.0
Current ratio
7.4
EBITDA (TTM)
—
Free cash flow (TTM)
−$42.27M
Quick ratio
7.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$72.05M
Latest balance sheet
Cash & equivalents
$72.05M
Total assets
$106.41M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$42.26M
Capital expenditures (TTM)
$3,000
R&D (TTM)
$47.56M
SG&A (TTM)
—
Stock compensation (TTM)
$6.20M
R&D / revenue
7,733.8%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
72
13F filer change QoQ
+16
Institutional ownership
36.8%
Conviction holders (share of 13F filers)
1.4%
Crowding (high-turnover and private-fund holders)
9.1%
Private-fund adviser ownership
8.1%
Active holders' share change QoQ
+9.6%
Holder tenure
8.2
Price vs estimated holder cost
-3.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.4%

Short interest

3 metrics
Short interest
4.7%
Latest settlement · 2.3 days to cover
Days to cover
2.3d
Short-squeeze score
65 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1479615 CUSIP 82686Q101 13F (30d) 7 filings 7 filers Visit website Investor relations